This group unites PH patients, caregivers, researchers and medical professionals in a platform to discuss the latest research and medical advances related to pulmonary hypertension. Information shared in this group is public.
Results published by the European Respiratory Journal in February 2018 reported Opsumit (Macitentan) failed to achieve the goals of a Phase 2 clinical trial over a 12-week period. Researchers concluded that patients treated with Opsumit were “quantitatively more likely to experience significant fluid retention versus placebo” and that the drug had no significant impact on the patients’ heart function. (Read more).
The FDA approved Opsumit for PH patients in 2013. Are you on this therapy? Did you participate in the trial? What symptoms do you experience?
Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.